• Je něco špatně v tomto záznamu ?

Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles

D. Saygin, H. Kim, C. Douglas, B. Erman, J. Wilkerson, JA. McGrath, CV. Oddis, IE. Lundberg, AA. Amato, I. García-De La Torre, H. Chinoy, D. Fiorentino, L. Chung, YW. Song, FW. Miller, N. Ruperto, J. Vencovsky, R. Aggarwal, LG. Rider,...

. 2023 ; 62 (11) : 3672-3679. [pub] 2023Nov02

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Intramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000752

Grantová podpora
HHSN273201600011C NIEHS NIH HHS - United States
ZIA AR041215 Intramural NIH HHS - United States
ZIA ES101081 Intramural NIH HHS - United States

OBJECTIVE: The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening. METHODS: Data from adult dermatomyositis/polymyositis patients in the rituximab (n = 147), etanercept (n = 14), and abatacept (n = 19) trials, and consensus patient profiles (n = 232) were evaluated. The Total Improvement Score (TIS), number of improving vs worsening CSMs, frequency of improvement with and without muscle-related CSMs, and contribution of PROM were evaluated by MRC category. Regression analysis was performed to assess contribution of each CSM to the MRC. RESULTS: Of 412 adults with dermatomyositis/polymyositis, there were 37%, 24%, 25%, and 14% with no, minimal, moderate, and major MRC improvement, respectively. The number of improving CSMs and absolute percentage change in all CSMs increased by improvement category. In minimal-moderate improvement, only physician-reported disease activity contributed significantly more than expected by MRC. Of patients with at least minimal improvement, 95% had improvement in muscle-related measures and a majority (84%) had improvement in PROM. Patients with minimal improvement had worsening in a median of 1 CSM, and most patients with moderate-major improvement had no worsening CSMs. Physician assessment of change generally agreed with MRC improvement categories. CONCLUSION: The ACR-EULAR MRC performs consistently across multiple studies, further supporting its use as an efficacy end point in future myositis therapeutic trials.

Charles University Prague Czech Republic

Department of Dermatology Stanford University School of Medicine Redwood City CA USA

Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston MA USA

Department of Rheumatology 1st Medical Faculty Institute of Rheumatology

Division of Rheumatology Department of Medicine Solna Karolinska Institutet Karolinska University Hospital Stockholm Sweden

Environmental Autoimmunity Group Clinical Research Branch National Institute of Environmental Health Sciences NIH Bethesda MD USA

Hospital General de Occidente de la Secretaría de Salud and Universidad de Guadalajara Department of Immunology and Rheumatology Mexico

IRCCS Istituto Giannina Gaslini UOSID Centro Trial Reumatologia Pediatria 2 PRINTO Genoa Italy

Juvenile Myositis Pathogenesis and Therapeutics Unit National Institute of Arthritis Musculoskeletal and Skin Diseases National Institutes of Health Bethesda MD USA

Medical Research Center Institute of Human Environment Interface Biology Department of Internal Medicine Seoul National University

National Institute for Health Research Manchester Biomedical Research Centre Division of Musculoskeletal and Dermatological Sciences Manchester University NHS Foundation Trust The University of Manchester Manchester UK

Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology Department of Medicine University of Pittsburgh Pittsburgh PA USA

Social and Scientific Systems Inc Durham NC USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000752
003      
CZ-PrNML
005      
20240213093345.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/kead110 $2 doi
035    __
$a (PubMed)36929923
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Saygin, Didem $u Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA $1 https://orcid.org/000000031675597X
245    10
$a Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles / $c D. Saygin, H. Kim, C. Douglas, B. Erman, J. Wilkerson, JA. McGrath, CV. Oddis, IE. Lundberg, AA. Amato, I. García-De La Torre, H. Chinoy, D. Fiorentino, L. Chung, YW. Song, FW. Miller, N. Ruperto, J. Vencovsky, R. Aggarwal, LG. Rider, International Myositis Assessment and Clinical Studies Group (IMACS)
520    9_
$a OBJECTIVE: The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening. METHODS: Data from adult dermatomyositis/polymyositis patients in the rituximab (n = 147), etanercept (n = 14), and abatacept (n = 19) trials, and consensus patient profiles (n = 232) were evaluated. The Total Improvement Score (TIS), number of improving vs worsening CSMs, frequency of improvement with and without muscle-related CSMs, and contribution of PROM were evaluated by MRC category. Regression analysis was performed to assess contribution of each CSM to the MRC. RESULTS: Of 412 adults with dermatomyositis/polymyositis, there were 37%, 24%, 25%, and 14% with no, minimal, moderate, and major MRC improvement, respectively. The number of improving CSMs and absolute percentage change in all CSMs increased by improvement category. In minimal-moderate improvement, only physician-reported disease activity contributed significantly more than expected by MRC. Of patients with at least minimal improvement, 95% had improvement in muscle-related measures and a majority (84%) had improvement in PROM. Patients with minimal improvement had worsening in a median of 1 CSM, and most patients with moderate-major improvement had no worsening CSMs. Physician assessment of change generally agreed with MRC improvement categories. CONCLUSION: The ACR-EULAR MRC performs consistently across multiple studies, further supporting its use as an efficacy end point in future myositis therapeutic trials.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a dermatomyozitida $x farmakoterapie $7 D003882
650    _2
$a konsensus $7 D032921
650    _2
$a výsledek terapie $7 D016896
650    12
$a polymyozitida $x farmakoterapie $7 D017285
650    12
$a myozitida $x farmakoterapie $7 D009220
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
700    1_
$a Kim, Hanna $u Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, USA $1 https://orcid.org/0000000205956533
700    1_
$a Douglas, Christian $u Social & Scientific Systems, Inc, Durham, NC, USA
700    1_
$a Erman, Brian $u Social & Scientific Systems, Inc, Durham, NC, USA
700    1_
$a Wilkerson, Jesse $u Social & Scientific Systems, Inc, Durham, NC, USA
700    1_
$a McGrath, John A $u Social & Scientific Systems, Inc, Durham, NC, USA
700    1_
$a Oddis, Chester V $u Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000260689212
700    1_
$a Amato, Anthony A $u Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a García-De La Torre, Ignacio $u Hospital General de Occidente de la Secretaría de Salud and Universidad de Guadalajara, Department of Immunology and Rheumatology, Mexico
700    1_
$a Chinoy, Hector $u National Institute for Health Research Manchester Biomedical Research Centre, Division of Musculoskeletal and Dermatological Sciences, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK $1 https://orcid.org/0000000164921288
700    1_
$a Fiorentino, David $u Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA
700    1_
$a Chung, Lorinda $u Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA
700    1_
$a Song, Yeong-Wook $u Medical Research Center, Institute of Human-Environment Interface Biology, Department of Internal Medicine, Seoul National University $1 https://orcid.org/0000000215759007
700    1_
$a Miller, Frederick W $u Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, USA
700    1_
$a Ruperto, Nicolino $u IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Reumatologia, Pediatria II, PRINTO, Genoa, Italy $1 https://orcid.org/0000000184077782
700    1_
$a Vencovsky, Jiri $u Department of Rheumatology, 1st Medical Faculty, Institute of Rheumatology; Charles University, Prague, Czech Republic
700    1_
$a Aggarwal, Rohit $u Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Rider, Lisa G $u Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, USA $1 https://orcid.org/0000000269122458
710    2_
$a International Myositis Assessment and Clinical Studies Group (IMACS)
773    0_
$w MED00011379 $t Rheumatology $x 1462-0332 $g Roč. 62, č. 11 (2023), s. 3672-3679
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36929923 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093342 $b ABA008
999    __
$a ok $b bmc $g 2049401 $s 1210446
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 11 $d 3672-3679 $e 2023Nov02 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
GRA    __
$a HHSN273201600011C $p NIEHS NIH HHS $2 United States
GRA    __
$a ZIA AR041215 $p Intramural NIH HHS $2 United States
GRA    __
$a ZIA ES101081 $p Intramural NIH HHS $2 United States
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace